Kempharm Weighted Average Shares Diluted Trend from 2010 to 2021

KMPH -  USA Stock  

USD 8.79  0.22  2.44%

Kempharm Weighted Average Shares Diluted is increasing over the last several years with slightly volatile swings. Weighted Average Shares Diluted is estimated to finish at about 4.3 M this year. During the period from 2010 to 2021 Kempharm Weighted Average Shares Diluted regressed destribution of quarterly values had coefficient of variationof 124.05 and r-squared of  0.72. Kempharm Selling General and Administrative Expense is most likely to increase significantly in the upcoming years. The last year's value of Selling General and Administrative Expense was reported at 7.92 Million. The current Weighted Average Shares is estimated to increase to about 4.3 M, while Consolidated Income is projected to decrease to (13.8 M).

Search Historical Trends 

 
Refresh
Check Kempharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kempharm main balance sheet or income statement drivers, such as Gross Profit of 14.6 M, Interest Expense of 4.7 M or Operating Expenses of 26.1 M, as well as many exotic indicators such as Asset Turnover of 1.26, Current Ratio of 1.14 or Gross Margin of 0.89. Kempharm financial statements analysis is a perfect complement when working with Kempharm Valuation or Volatility modules. It can also supplement various Kempharm Technical models. Please see Stocks Correlation.

Kempharm Quarterly Weighted Average Shares Diluted

29.17 MillionShare

Kempharm Weighted Average Shares Diluted Breakdown

Showing smoothed Weighted Average Shares Diluted of Kempharm with missing and latest data points interpolated. The weighted average number of shares or units issued and outstanding that are used by the company to calculate [EPSDil]; determined based on the timing of issuance of shares or units in the period.Kempharm's Weighted Average Shares Diluted historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kempharm's overall financial position and show how it may be relating to other accounts over time.
Weighted Average Shares Diluted10 Years Trend
Increasing
Slightly volatile
 Weighted Average Shares Diluted 
Share
      Timeline 

Kempharm Weighted Average Shares Diluted Regression Statistics

Arithmetic Mean 1,190,250
Geometric Mean 562,218
Coefficient Of Variation 124.05
Mean Deviation 1,093,147
Median 912,316
Standard Deviation 1,476,539
Range 4,146,448
R-Value 0.85
R-Squared 0.72
Significance 0.00045115
Slope 348,406

Kempharm Weighted Average Shares Diluted History

2015460.5 K
2016912.3 K
2017915.8 K
20181.1 M
20191.9 M
2020M
20214.3 M

About Kempharm Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Kempharm income statement, its balance sheet, and the statement of cash flows. Kempharm investors use historical funamental indicators, such as Kempharm's Weighted Average Shares Diluted, to determine how well the company is positioned to perform in the future. Although Kempharm investors may use each financial statement separately, they are all related. The changes in Kempharm's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Kempharm's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Kempharm Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Kempharm. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Weighted Average Shares DilutedM4.3 M
Average Assets10.9 M11.2 M
Average Equity-65.1 M-70.2 M
Invested Capital Average19.6 M20.1 M
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kempharm without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Crypto Correlations Now

   

Crypto Correlations

Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kempharm using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Stocks Correlation. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.